Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aceragen Inc ACGN

Healthcare Biotechnology
Aceragen, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and... see more

Recent & Breaking News (NDAQ:ACGN)

Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2018

Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting

GlobeNewswire April 17, 2018

Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma

GlobeNewswire April 16, 2018

BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger

Business Wire April 10, 2018

Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals

GlobeNewswire April 2, 2018

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

GlobeNewswire March 22, 2018

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update

GlobeNewswire March 7, 2018

Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)

GlobeNewswire March 1, 2018

BioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger

GlobeNewswire February 27, 2018

Lifshitz & Miller LLP Announces Investigation of Advance Auto Parts, Inc., Ballard Power Systems, Inc., Connecture, Inc., Idera Pharmaceuticals, Inc., Impinj Inc., Obalon Therapeutics, Inc., and Super Micro Computer, Inc.

PR Newswire February 19, 2018

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences

GlobeNewswire February 19, 2018

RM LAW Announces Investigation of Idera Pharmaceuticals, Inc.

PR Newswire January 30, 2018

IDERA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger

Business Wire January 24, 2018

Pharma M&A Picks Up Momentum

Benzinga.com  January 23, 2018

38 Biggest Movers From Yesterday

Benzinga.com  January 23, 2018

SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Idera Pharmaceuticals, Inc. - IDRA

PR Newswire January 22, 2018

Mid-Afternoon Market Update: Bioverativ Climbs Following $105/Share Offer From Sanofi; Recon Technology Shares Drop

Benzinga.com  January 22, 2018

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Idera Pharmaceuticals, Inc. (IDRA) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire January 22, 2018

32 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  January 22, 2018

Mid-Day Market Update: Juno Therapeutics Surges On Acquisition News; Sanmina Shares Plummet

Benzinga.com  January 22, 2018